Track Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) CYTO Open Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) in new tab

0.3000 USD
P/E
0.16
EPS
1.82
P/B
0.13
ROE
-368.78
Beta
2.44
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
P/E0.16
EPS1.82
Book Value2.37
Price to Book0.13
Debt/Equity6.77
% Insiders0.529%
Estimates
Forward P/E-0.26
Forward EPS-1.34

DCF Valuation

Tweak assumptions to recompute fair value for Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) (CYTO)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) Logo Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) Analysis (CYTO)

Bermuda Health Care Official Website Stock

Is Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) a good investment? Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) (CYTO) is currently trading at 0.3000 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.16. This relatively low multiple may signal that Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) is undervalued compared to historical market norms.

Investor FAQ

Does Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) pay a dividend?

No, it does not currently pay a dividend.

What asset class is Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda)?

Altamira Therapeutics Ltd. 0.2 Common Shares (Bermuda) is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.

Exchange Ticker
NMS (United States) CYTO

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
March 14, 2018 0.100000
May 1, 2019 0.050000
Oct. 25, 2022 0.050000
Dec. 13, 2023 0.050000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion